+5.2%
ZTS vs MRNA
+794.5%
-789.3%
-70.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.5% | -4.8% | +7.3% | +2.7% |
| 7D | +3.6% | -20.9% | +24.5% | +4.7% |
| 30D | +8.2% | -13.3% | +21.5% | +8.8% |
| 3M | +16.5% | +212.6% | -196.1% | +6.4% |
| 6M | +11.6% | +309.0% | -297.4% | -0.4% |
| YTD | -30.5% | +567.3% | -597.8% | -40.3% |
| 1Y | -25.9% | +689.7% | -715.6% | -37.3% |
| 3Y | -48.8% | +157.4% | -206.2% | -54.4% |
| 5Y | -59.6% | -21.7% | -37.9% | -62.6% |
| All | +5.2% | +794.5% | -789.3% | -13.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling